dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
=== Electric vehicles === In February 2023, Moore introduced the Clean Transportation and Energy Act, which increases incentives for people and businesses looking to purchase electric trucks and charging stations. In March 2023, he said he supported adopting California's Advanced Clean Cars II (ACC II) regulation, which would phase out the sale of gas-powered cars in the state by 2035. In April 2023, he signed the Clean Transportation and Energy Act and several other bills aimed at strengthening the state's offshore wind energy industry into law. In August 2023, Moore said he supported a proposal by then-Governor Hogan to delay emissions testing on new cars from three to six years—despite initially withdrawing the proposal earlier in his term due to equity concerns—after the Maryland Motor Vehicle Administration found that the change would have no severe impacts on equity. In April 2025, as Maryland electric vehicle sales continued to lag behind the state's goals, Moore signed an executive order to delay fines against car companies that fail to comply with the state's electric vehicle mandates.
=== Signaling pathways used in electrotaxis === In the absence of a complete explanation of the mechanism behind electrotaxis, certain signaling pathways have been found to have an involvement in electrotaxis. In both neutrophils and keratinocytes, Zhau et al. experimentally determined that physiological strength EFs induce phosphorylation of extracellular-signal-regulated kinase (ERK), p38 mitogen-activated Kinase (MAPK), Src, and Akt on ser 473. In chemotaxis, Src and Akt are polarized by phosphatidylinositol-3-OH kinase-γ (PI(3)Kγ) activation and inhibition of phosphate tensin homolog (PTEN). In the experiment, phosphorylated Src polarized in the direction of migration when influenced by physiological strength EFs, as is also seen in chemotaxis. Phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3), another molecule used in signaling, polarized to the leading edge of HL60 cells when subjected to an EF. Upon reversal of the EF, polarization PtdIns(3,4,5)P3 rapidly reversed to the new direction of migration. Treatment with lantruculin did not prevent this from occurring, indicating that polarization is not actin-dependent. Cells in which the gene encoding PI(3)Kγ, Pik3cg, was disrupted exhibited reduced electrotaxic responses. Pharmocological inhibition of PI(3)K in keratinocytes produced the same results. Similarly, genetic disruption of PTEN resulted in increased phosphorylation of ERK and Akt and a greater electrotaxic response. Consideration of these results suggests that PI(3)Kγ and PTEN are involved in the signaling pathway used in electrotaxis.
Grinners Food Systems Limited, the franchiser of Greco Pizza (since 1981) and Captain Sub, is a Truro, Nova Scotia-based company. It is owned by Trucorp Investments Incorporated. Trucorp, headquartered in Dieppe, New Brunswick, also owns Bonte Foods Limited, Frank and Gino's Restaurants, and Chris Brothers food products. Established in Moncton, New Brunswick in 1977, Greco Pizza is one of Atlantic Canada's largest pizza chains. Menu items include pizza, donair, salads, garlic fingers, and the restaurant's proprietary dipping sauces. Many of the over 170 locations in Quebec, Ontario, New Brunswick, Nova Scotia, and Newfoundland operate co-branded with Captain Submarine. Both are quick-service restaurants. Captain Submarine was acquired by Grinner's in 2002, when it only had nine locations (21 fewer than it had in the 1980s). Many of the stores franchised since then also sell Greco Pizza items. The purchase brought the number of Grinners franchised restaurants from 111 to 120.
Sources: en.wikipedia.org
== Business, finance, and economics == Safety improvement plan, a plan for improving safety Sales incentive plan, a type of employee incentive program Securities information processor, the part of public infrastructure for disseminating market data in the United States Share Incentive Plan, a UK government approved employee plan Systematic investment plan, an investment strategy
== Pathology == Tuftsin deficiency can be hereditary or can occur following splenectomy, resulting in increased susceptibility to certain diseases e.g.: infected eczematous dermatitis with draining lymph nodes, otitis and sinusitis. Acquired tuftsin deficiency can occur in granulocyte leukemia, when blood neutrophils failed to show stimulation with synthetic tuftsin or with the serum leukokinin. Serum level of tuftsin was minimal or absent.
Tourism in Brazil is a growing sector and key to the economies of several regions of the country. The country had 6.36 million visitors in 2015, ranking in terms of the international tourist arrivals as the main destination in South America and second in Latin America after Mexico. Revenues from international tourists reached US$6 billion in 2010, showing a recovery from the 2008–2009 economic crisis. Historical records of 5.4 million visitors and US$6.8 billion in receipts were reached in 2011. In the list of world tourist destinations, in 2018, Brazil was the 48th most visited country, with 6.6 million tourists (and revenues of 5.9 billion dollars). Natural areas are its most popular tourism product, a combination of ecotourism with leisure and recreation, mainly sun and beach, and adventure travel, as well as cultural tourism. Among the most popular destinations are the Amazon Rainforest, beaches and dunes in the Northeast Region, the Pantanal in the Center-West Region, beaches at Rio de Janeiro and Santa Catarina, cultural tourism in Minas Gerais and business trips to São Paulo. In terms of the 2024 Travel and Tourism Competitiveness Index (TTCI), which is a measurement of the factors that make it attractive to develop business in the travel and tourism industry of individual countries, Brazil ranked in the 26th place at the world's level, third in the Americas, after Canada and United States. Domestic tourism is a key market segment for the tourism industry in Brazil.
Sources: en.wikipedia.org
Meat trimmings and fat Flavorings, such as salt, garlic, and paprika Preservatives (cure) – typically sodium erythorbate and sodium nitrite Pork and beef are the traditional meats used in hot dogs. Less expensive hot dogs are often made from chicken or turkey, using low-cost mechanically separated poultry. Changes in meat technology and dietary preferences have led manufacturers to lower the salt content and use turkey, chicken, and vegetarian meat substitutes.
Disulfide bonds in proteins are formed by oxidation of the thiol group of cysteine residues. The other sulfur-containing amino acid, methionine, cannot form disulfide bonds. More aggressive oxidants convert cysteine to the corresponding sulfinic acid and sulfonic acid. Cysteine residues play a valuable role by crosslinking proteins, which increases the rigidity of proteins and also functions to confer proteolytic resistance (since protein export is a costly process, minimizing its necessity is advantageous). Inside the cell, disulfide bridges between cysteine residues within a polypeptide support the protein's tertiary structure. Insulin is an example of a protein with cystine crosslinking, wherein two separate peptide chains are connected by a pair of disulfide bonds. Protein disulfide isomerases catalyze the proper formation of disulfide bonds; the cell transfers dehydroascorbic acid to the endoplasmic reticulum, which oxidizes the environment. In this environment, cysteines are, in general, oxidized to cystine and are no longer functional as a nucleophiles. Aside from its oxidation to cystine, cysteine participates in numerous post-translational modifications. The nucleophilic thiol group allows cysteine to conjugate to other groups, e.g., in prenylation. Ubiquitin ligases transfer ubiquitin to its pendant, proteins, and caspases, which engage in proteolysis in the apoptotic cycle. Inteins often function with the help of a catalytic cysteine.
Gunboat diplomacy March–May 2025 United States attacks in Yemen Operation Inherent Resolve US intervention in Somalia (2007–present) Ecuadorian conflict (2024–present) Shield of the Americas Joint Interagency Task Force-Counter Cartel
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.